Can one simple blood test help slow progression of chronic kidney disease and improve type 2 diabetes control in just 12 months? Yes it can. We just proved it (again, as we already proved it with our 6 month data). Check out our just published Real World Evidence which features 12 months of follow-up data in 2,469 patients with type 2 diabetes and early-stage chronic kidney disease at a major health system. The published results demonstrate the effect seen at 6 months are maintained at 1 year, providing confidence that even a single KidneyIntelX risk assessment test can deliver durable benefits in terms of clinician and patient behavior and hard outcomes. We were able to demonstrate that our KidneyIntelX bioprognostic test resulted in improved adherence to guideline recommended care, including the use of SGLT2i and GLP1 RAs at 66% and 64% in high and intermediate risk patients post-testing, far exceeding national averages. The reported improvement in key cardio-metabolic health metrics also demonstrate the patient health benefits are beyond kidney disease. This includes: - a reduction in the rate of kidney function decline (eGFR slope), AND - improved A1C levels, AND - an increase in the percentage of KidneyIntelX high-risk patients who achieved blood pressure control See data here: https://lnkd.in/e59rcWaB Holly Kramer Katherine Tuttle Steven Coca Girish Nadkarni Thomas McLain Fergus Fleming Michael J. Donovan PhD, MD
Ruth V Gilbert
9mo
Imagine the leap forward in stemming the tide of UK NCD's if this was deployed both via NHS practices and via insurance / employee wellness programmes. The tech ecosystem already exists to deliver this, just need stakeholders to see the benefit.
Craig T. Ingram
9mo
This is fantastic 🎉🎉
these are great results Sharon. I wonder how many other great results you have to produce before major hospitals and health insurers finally give patients the treatment which they deserve.